Factor V Leiden, C>T MTHFR Polymorphism and Genetic Susceptibility to Preeclampsia

Summary

We performed a case-controlled study to investigate whether the FV Leiden mutation and the C>T⁶⁷⁷ polymorphism of the 5,10 methylene tetrahydrofolate reductase (MTHFR) are associated with the occurrence of preeclampsia in 96 otherwise healthy preeclamptic women and 129 parous women as controls. FV Leiden carriers were 10 (10.5%) in cases and 3 (2.3%) in controls (OR: 4.9, 95% Cl: 1.3-18.3). MTHFR TT homozygotes were 28 (29.8%) in cases and 24 (18.6%) in the control group (OR: 1.8,95% Cl 1.0-3.5). No difference in any of the polymorphisms was found between proteinuric (n = 45) and non-proteinur-ic (n = 51) patients. Moreover, MTHFR polymorphism does not affect the association between FV Leiden and preeclampsia. In conclusion, FV Leiden mutation and MTHFR TT genotype are associated with the occurrence of preeclampsia, suggesting that, during pregnancy, women carrying these gene variants are prone to develop such a complication.

• References

• 1 National High Blood Pressure Education Program Working Group report on high blood pressure in pregnancy. Am J Obstet Gynecol 1990; 163: 1691-1712
• 2 Cooper DW, Brennecke SP, Wilton AN. Genetics of preeclampsia. Hypertens Pregnancy 1993; 12: 01-23
• 3 Liston WA, Kilpatrick DC. Is genetic susceptibility to preeclampsia conferred by homozygosity for the same single recessive gene in mother and fetus?. Br J Obstet Gynaecol 1991; 98: 1079-1086
• 4 Amgrìmsson R, Purandare S, Connor M, Walker JJ, Björnsson S, Soubrier F, Kotelevtsen YV, Geirsson RT, Björnsson H. Angiotensinogen: a candidate gene involved in preeclampsia?. Nature Genet 1993; 04: 114-115
• 5 Ward K, Hata A, Jeunemaitre X, Helin C, Nelson L, Namikawa L, Farrington PF, Ogasawara M, Suzumori K, Tomoda S, Berrebi S, Sasaki M, Corvol P, Lifton RP, Lalouel JM. A molecular variant of angiotensinogen associated with preeclampsia. Nature Genet 1993; 04: 59-61
• 6 Greer IA. Pathological processes in pregnancy-induced hypertension and intrauterine growth retardation: ‘ an excess of heated blood’. In: Haemostasis and Thrombosis in Obstetrics and Gynaecology. Greer IA, Turpie AGG, Forbes CD. (eds) London: Chapman and Hall; 1992. 163-202
• 7 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de RondeH, van derVelden P A, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
• 8 Svensson PI, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-522
• 9 Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994; 14: 1080-1083
• 10 Preston FE, Rosendaal FR, Walker ID, Briët E, Berntorp E, Conard J, Fontcuberta J, Makris M, Mariani G, Noteboom W, Pabinger I, Legnani C, Scharrer I, Schulman S, van derMeer F JM. Increased fetal loss in women with heritable thromphilia. Lancet 1996; 348: 913-916
• 11 Grandone E, Margaglione M, Colaizzo D, d’Addedda M, Cappucci G, Vecchione G, Sciannamé N, Pavone G, Di MinnoG. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost 1997; 77: 822-824
• 12 Dizon-Townson DS, Nelson LM, Easton K, Ward K. The Factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996; 175: 902-905
• 13 Mudd SH, and Levy HL. Disorders of transsulfuration. In the Metabolic basis of inherited disease. Scriver CR, Beaudet AL, Sly WS, and Valle D. editors McGraw- Hill; New York: 1989. 693-734
• 14 Mudd SH, Skovby FLevy. et al The natural history of homocystinuria due to cystathionine b-synthase deficiency. Am J Hum Genet 1985; 37: 01-31
• 15 Burke G, Robinson K, Refsum H, Stuart B, Drumm J, Graham I. Intrauterine growth retardation perinatal death and maternal homocysteine levels. N Engl J Med 1992; 326: 69-70
• 16 Mandel H, Brenner B, Berant M, Rosenberg N, Lanir N, Jakobs C, Fowler B, Selig-sohn U. Coexistence of hereditary homocystinuria and Factor V Leiden - Effect on thrombosis. N Engl J Med 1996; 334: 763-768
• 17 Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, van denHeuvel L P, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113
• 18 De FranchisP, Mancini FP, D’Angelo A, Sebastio G, Fermo I, De StefanoJ, Margaglione M, Mazzola G, Di MinnoG, Andria G. Elevated total plasma homocysteine and C>T mutation of the 5,10-methylenetetrahydrofolate reductase gene in thrombotic vascular disease. Am J Hum Genet 1996; 59: 262-264
• 19 Cattaneo M, Tsai MY, Bucciarelli P, Taioli E, Zighetti ML, Bignell M, Mannucci ’ PM. A common mutation in the methylene-tethrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant Factor V (Factor V:Q⁵⁰⁶). Blood 1996; 88: 10 (Suppl. 01) (abstract)
• 20 Quéré I, Dupuy E, Chadefaux-Veckemans B, Bellet H, Biron C, Kamoun P, Tobelem G, Janbon C. Homocysteine and deep vein thrombosis: C677T MTHFR genetic thermolabile variant and folic acid modulation of plasma homocysteine levels. Haemostasis. 1996: 26 (suppl 03) (abstract)
• 21 Steegers-Theunissen RPM, Boers GHJ, Blom HJ, Trijbels FJM, Eskes TKAB. Hyperhomocysteinaemia and recurrent spontaneous abortion or abruptio placentae. Lancet 1992; 339: 1122-1123
• 22 Dekker GA, de VriesygJIP, Doelitzsch PM, Huijgens PC, von BlombergBME, Jakobs C, van GeijnHP. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995; 173: 1042-1048
• 23 Davey DA, Mac GillivrayI. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol 1988; 158: 892-898
• 24 Rees DC, Cox M, Clegg JB. World distribution of FV Leiden. Lancet 1995; 346: 1133-1134
• 25 Davies JA, Prentice CRM. Coagulation changes in pregnancy-induced hypertension and growth retardation. In Haemostasis and Thrombosis in Obstetrics and Gynaecology. Edited by Greer IA, Turpie AGG, Forbes CD. London: Chapman and Hall; 1992. 143-162
• 26 Douglas JT, Shah M, Lowe GDO, Belch JJF, Forbes CD, Prentice CRM. Plasma fi-brinopeptide A and betathromboglobulin in pre-eclampsia and pregnancy hypertension. Thromb Haemost 1982; 47: 54-55
• 27 Aznar J, Gilabert J, Estellés A, Espana F. Fibrinolytic activity and protein C in pre-eclampsia. Thromb Haemost 1986; 55: 314-317
• 28 Malinow MR, Kang SS, Taylor LM, Wong PWK, Coull B, Inahara T, Mukerjee D, Sexton G, Upson B. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 1989; 79: 1180-1188
• 29 Guttormsen AB, Ueland PM, Nesthus I, Nygard O, Schneede J, Vollset SE, Refsum H. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (≥40 μmol/liter). J Clin Invest 1996; 98: 2174-2183
• 30 Mac Gillivray. Some observations on the incidence of pre-eclampsia. J Obstet Gynecol Br Commonw 1958; 65: 536
• 31 Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-1035
• 32 Zöller B, Berntsdotter A, de FrutosPG, Dahlback B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-3523
• 33 Grandone E, Margaglione M, Colaizzo D, Montanaro S, Pavone G, Di MinnoG. Presence of FV Leiden and MTHFR mutation in a patient with complicated pregnancies. Thromb Haemost 1997; 77: 1036